
Nautilus reports Q3 2026 results with $0.2M revenue, $15.6M net loss, and advances in proteome analysis tech.
Nautilus Biotechnology announced its Q3 2026 financial results, reporting $0.2 million in revenue mainly from grants and early access services, and a net loss of $15.6 million. The company highlighted progress in its proteome analysis platform, inclu...





